Aktienanalyse zu Stevanato Group SpA (STVN)STVNStevanato Group SpA

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).

Stevanato Group (STVN) is currently priced at $18.90, which is below several analyst price targets, including $22 from Deutsche Bank and $25 from TD Cowen. However, the stock has a low RSI of 18.47, indicating it is oversold, but it also has a significant risk with a 1-year change of -26.91%. This suggests that while there may be potential for recovery, the stock is currently under pressure and may not be a strong buy at this moment.